Abstract:Objective To compare the effect of mitiglinide and repaglinide on glycometabolism,cardiovascular risk factors and oxidative stress in patients with newly diagnosed type 2 diabetes mellitus(T2DM).Methods Ninety newly diagnosed T2DM patients were randomly assigned to group A and group B.The patients of group A received repaglinide plus metformin treatment,while those of group B were given mitiglinide plus metformin treatment.Continuous glucose monitoring system(CGMS) was used to record the dynamic changes and fluctuation of blood glucose in all patients during the first 3 days.All the patients were followed up to examine the corresponding indices after 12 weeks.Results After treatment for 3 days,the fasting blood glucose(FBG),mean blood glucose(MBG) at 30 min,and 1,2 and 3 h after meals,and 24 h MBG decreased in both groups.The decrease of 1 h MBG and 2 h MBG was more significant in group B than in group A(P < 0.05),while the mean amplitude of glycemic excursion(MAGE) was significantly lower in group B than in group A(P < 0.05).Twelve weeks later,FBG and postprandial blood glucose(1 h PBG and 2 h PBG) significantly decreased in both groups(P < 0.05),and the decrease in group B was more significant than that in group A(P < 0.05).Fasting insulin(FINS) and postprandial insulin(1 h INS and 2 h INS) increased in both groups,and the increase of 1 h INS and 2 h INS was more significant in group B than in group A(P < 0.05).Glycosylated hemoglobin-A 1c(HbA 1c) in both groups decreased(P <0.05),and the decrease was more significant in group B than in group A.Both groups could significantly decrease the level of HOMA insulin resistance(HOMA-IR) and increase the level of insulin sensitive index(ISI)(P < 0.05),and the effect was more significant in group B than in group A(P < 0.05).The proportion of hypoglycemia in group B was lower than that in group A.Both groups could partly decrease the levels of total cholesterol(TC),triglycerides(TG) and fibrinogen(FG),and increase the level of high-density lipoprotein cholesterol(HDL-c).However,they had no significant effect on plasminogen activator inhibitor-1(PAI-1)(P >0.05).Both groups could decrease the level of superoxide dismutase(SOD) and increase the level of malondialdehyde(MDA),and the effect was more significant in group B than in group A(P <0.05).Conclusion For newly diagnosed T2DM,both mitiglinide and repaglinide can decrease FBG and PBG significantly in a short term,but mitiglinide can keep MAGE more steadily.After a long period of therapy,mitiglinide can significantly decrease the levels of cardiovascular risk factors and suppress antioxidative stress with lower incidence of hypoglycemia as compared with repaglinide.

Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis

Comparative effects of fixed-dose mitiglinide/voglibose combination and glimepiride on vascular endothelial function and glycemic variability in patients with type 2 diabetes: A randomized controlled trial

Efficacy and Safety of Combination Therapy with Vildagliptin and Metformin Versus Metformin Uptitration in Chinese Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A Randomized, Open-Label, Prospective Study (Vision)

EVALUATION OF THE SAFETY AND EFFICACY OF TRIPLE DRUG COMBINATION OF VOGLIBOSE 0.2 MG, GLIMEPIRIDE 1MG/ 2MG AND METFORMIN 500 MG IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED WITH DUAL THERAPY

Glycemic/metabolic responses to identical meal tolerance tests at breakfast, lunch and dinner in Japanese patients with type 2 diabetes mellitus treated with a dipeptidyl peptidase-4 inhibitor and the effects of adding a mitiglinide/voglibose fixed-dose combination

Efficacy and Safety of Vildagliptin and Metformin Combination Therapy in Type 2 Diabetes

Efficacy and Safety of Insulin Combined with Vildagliptin in the Treatment of Type 2 Diabetic Patients with Moderate Renal Impairment

Efficacy and Safety of Mitiglinide Versus Nateglinide in Newly Diagnose Patients with Type 2 Diabetes Mellitus: A Randomized Double Blind Trial

Evaluating the Efficacy, Safety, and Tolerability of Combination Therapy of Dapagliflozin and Linagliptin Over Dapagliflozin and Vildagliptin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

Efficacy and Safety of Combination Therapy with Vildagliptin and Metformin Versus Metformin Up-Titration in Chinese Patients with Type 2 Diabetes Mellitus: Study Design and Rationale of the Vision Study

Efficacy and Safety of Additional Basal Insulin or Oral Antidiabetic Drug in Type 2 Diabetes Poorly Controlled with One Oral Antidiabetic Drug

Mitiglinide for type 2 diabetes treatment

Data on vildagliptin and vildagliptin plus metformin combination in type-2 diabetes mellitus management

Multicentre, Double-blind, Randomized Study of Mitiglinide Compared with Nateglinide in Type 2 Diabetes Mellitus Patients in China

Effectiveness and Safety of Metformin, Teneligliptin, and Glimepiride Combination Therapy in Type 2 Diabetes: A Quasi Experimental Clinical Trial

Efficacy and Safety of a Fixed-Dose Combination of Vildagliptin and Pioglitazone in Indian Patients With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Comparative, Phase III Study

Glargine insulin/gliclazide MR combination therapy is more effective than premixed insulin monotherapy in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs.

Combination of retagliptin and henagliflozin as add‐on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, active‐controlled, phase 3 trial

Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk

Effect of Combined Treatment of Glimepiride and Glargine for Type 2 Diabetes Mellitus

Clinical efficacy of mitiglinide and repaglinide in treatment of patients with newly diagnosed type 2 diabetes mellitus